Gp91ds-tat, a Selective NADPH Oxidase Peptide Inhibitor, Increases Blood Nitric Oxide (NO) Bioavailability in Bind Limb Ischemia and Reperfusion (I/R) by Walker, Sydney et al.
Gp91ds-tat, a selective NADPH oxidase peptide inhibitor, increases blood nitric 
oxide (NO) bioavailability in hind limb ischemia and reperfusion (I/R) 
Sydney Walker, Tyler Galbreath, Qian Chen, Robert Barsotti, Cathy Hatcher, Harsh Patel, William Chau, Lindon Young 
Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine 
4170 City Avenue, Philadelphia, PA 19131 
Introduction Methods 
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 We hypothesized that gp91ds-tat will attenuate I/R induced 
increase in H2O2 levels and decrease in NO levels in the blood 
when compared to the sham hind limb within the same rat. We 
expect that the gp91ds-tat treated rats will show a decrease in 
H2O2 blood levels and increased NO blood levels compared to 
the non-drug treated controls. As an outcome, there will be a 
decrease in ROS release and endothelial dysfunction. 
 
  I/R injury can cause an increase in blood H2O2 levels and a 
decrease in endothelial-derived NO bioavailability. A significant 
reduction of blood H2O2 levels and a significant increase in endothelial-
derived NO bioavailability was observed in gp91ds-tat treated SD rats 
compared to the saline controls. The results of this study support our 
hypothesis that the NADPH oxidase peptide inhibitor, gp91ds-tat,  
significantly attenuates reperfusion-induced ROS release and leads to 
an increase in NO bioavailability. Overall, the data suggests that 
NADPH oxidase inhibitors like gp91ds-tat, may be a viable therapeutic 
option for future clinical use in I/R injury.   
Male Sprague-Dawley (SD) rats (275-325 grams, Charles River, Springfield, MA) 
were anesthetized with an induction dose of 60 mg/kg and maintenance dose of 30 
mg/kg sodium pentobarbital intraperitoneally (i.p.). The rats also received an 
anticoagulant, sodium heparin (1000 USP units/mL) i.p. We measured blood H2O2 or 
NO levels from both femoral limbs in real-time: one limb was subjected to I/R while 
the other was used as a non-ischemic sham control. H2O2 or NO microsensors (100 
μm, WPI Inc., Sarasota, FL) were connected to a free radical analyzer (Apollo 4000, 
WPI Inc.) and were inserted into a catheter placed in each femoral vein (Figure 3). 
Ischemia was induced by clamping the femoral artery and vein of one limb for 30 
min followed by 45 min of reperfusion. Gp91ds-tat (1.2 mg/kg) or saline (for control 
group) was given as a bolus injection via the jugular vein at the beginning of 
reperfusion. We continuously monitored the H2O2 or NO release and reported data 
collected at 5 min intervals during the 15 min baseline, 30 min ischemia and 45 min 
reperfusion periods. The changes in H2O2 or NO release during reperfusion are 
expressed as relative change to baseline after correction to the calibration curve of 
H2O2 (μM) or NO (nM) microsensors. Experimental group data was compared by 
Student‘s t-test with p<0.05 considered statistically significant.  
Figure 6. The relative change in NO release in the blood between the I/R and sham femoral hind limbs 
(IR-Sham) during reperfusion between saline and gp91ds-tat treated SD rats. A significant increase 
was observed in NO release in the gp91ds-tat treated group at 10 min and 20-45 min of reperfusion 
ranged between 68 nM and 146 nM. (gp91ds-tat * p<0.05, **p<0.01 from saline).  
Figure 3. The experimental preparation for measuring blood H2O2 or NO release from I/R and 
sham femoral veins in the male SD rats. 
 
Hypothesis 
Figure 5. The comparison of H2O2 release in the blood between the I/R and sham femoral hind 
limbs (IR-Sham) during reperfusion between saline and gp91ds-tat treated SD rats. A significant 
decrease was observed in H2O2 release in the gp91ds-tat treated group at 20 min and 40-45 min 
of reperfusion that ranged between 0.65 μM and 1.33 μM. (gp91ds-tat * p<0.05, **p<0.01 from 
saline).  
 I/R injury induces cell death and organ dysfunction in large part 
due to a burst of reactive oxygen species that occurs upon the 
reintroduction of oxygen into the ischemic tissue area, leading to 
vascular endothelial dysfunction. This dysfunction causes decreased 
blood NO bioavailability and increased hydrogen peroxide (H2O2) levels. 
Previously we have shown that gp91ds-tat, a selective NADPH oxidase 
inhibitor, attenuated cardiac contractile dysfunction and reduced infarct 
size compared to controls in isolated rat hearts subjected to I/R injury.  
We speculate this occurs due to inhibition of NADPH oxidase-induced 
superoxide release.(1)  NADPH oxidase is activated during I/R injury via 
cytokine receptor stimulation and utilizes molecular oxygen to produce 
superoxide. Gp91ds-tat selectivity inhibits NADPH oxidase assembly by 
blocking  p47phox interaction with gp91phox, also known as NOX2, and is 
principally expressed in endothelial and myeloid cells. Superoxide (SO) 
overproduction from activated NADPH oxidase can quench NO via the 
formation of peroxynitrite and also be converted to H2O2 in blood via 
superoxide dismutase. Peroxynitrite can further cause endothelial NO 
synthase uncoupling which produces SO instead of NO.(2)  To 
understand the potential cardioprotective mechanism of gp91ds-tat, we 
performed real-time analyses of blood NO bioavailability and H2O2 levels 
using our rat hind limb I/R model. 
Figure 2. Schematic showing the inactive and active forms of NADPH oxidase. Green-lines 
denote areas of inhibition performed by gp91ds-tat. Adapted from Wilkinson et al. (4) 
Figure 1. gp91ds-tat sequence (1.2 mg/kg, MW: 2452 g/mol) Adapted from Rey et al. (3) Results 
Figure 4. The time course of change relative to baseline in the saline control group of H2O2 (μM) 
or NO (nM) from anesthetized male SD rat femoral limbs. (a) A significant increase in H2O2 
release occurred from 10 min to 45 min reperfusion that ranged between 1.3μM and 1.4μM from 
I/R compared to sham limbs in saline controls (* p<0.05, **p<0.01 from sham).  
(b)  There was a significant decrease in NO release that ranged between -70nM to -87nM from 
I/R compared to sham limbs during the last 15 min (30-45 min) of reperfusion in saline controls.  
(* p<0.05 from sham).  
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